Goldman Sachs
NRIX icon

Goldman Sachs’s Nurix Therapeutics NRIX Stock Holding History

Goldman Sachs’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7M Sell
813,589
-505,070
-38% -$8.6M ﹤0.01% 2638
2026
Q1 		$20.4M Buy
1,318,659
+241,086
+22% +$4M ﹤0.01% 2413
2025
Q4 		$20.4M Buy
1,077,573
+455,274
+73% +$6.54M ﹤0.01% 2352
2025
Q3 		$5.75M Buy
622,299
+37,780
+6% +$392K ﹤0.01% 3514
2025
Q2 		$6.66M Buy
584,519
+77,048
+15% +$833K ﹤0.01% 3149
2025
Q1 		$6.03M Buy
507,471
+44,002
+9% +$736K ﹤0.01% 3167
2024
Q4 		$8.73M Sell
463,469
-49,752
-10% -$1.14M ﹤0.01% 2931
2024
Q3 		$11.5M Buy
513,221
+48,714
+10% +$1.1M ﹤0.01% 2575
2024
Q2 		$9.69M Sell
464,507
-28,159
-6% -$439K ﹤0.01% 2536
2024
Q1 		$7.24M Buy
492,666
+210,766
+75% +$2.27M ﹤0.01% 2767
2023
Q4 		$2.91M Sell
281,900
-81,626
-22% -$559K ﹤0.01% 3623
2023
Q3 		$2.86M Buy
363,526
+40,878
+13% +$373K ﹤0.01% 3475
2023
Q2 		$3.22M Sell
322,648
-218,062
-40% -$2.22M ﹤0.01% 3499
2023
Q1 		$4.8M Sell
540,710
-80,938
-13% -$843K ﹤0.01% 3111
2022
Q4 		$6.83M Sell
621,648
-203,431
-25% -$2.45M ﹤0.01% 2907
2022
Q3 		$10.8M Buy
825,079
+493,236
+149% +$7.81M ﹤0.01% 2440
2022
Q2 		$4.2M Buy
331,843
+16,177
+5% +$183K ﹤0.01% 3310
2022
Q1 		$4.42M Buy
315,666
+7,179
+2% +$127K ﹤0.01% 3467
2021
Q4 		$8.93M Buy
308,487
+183,772
+147% +$5.57M ﹤0.01% 2879
2021
Q3 		$3.74M Sell
124,715
-156,137
-56% -$4.82M ﹤0.01% 3602
2021
Q2 		$7.45M Sell
280,852
-66,241
-19% -$1.94M ﹤0.01% 2982
2021
Q1 		$10.8M Buy
347,093
+187,544
+118% +$7.1M ﹤0.01% 2496
2020
Q4 		$5.25M Buy
+159,549
New +$5.29M ﹤0.01% 2961

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs's NRIX Position: Q2 2026 in Review

Goldman Sachs reduced its Nurix Therapeutics (NRIX) stake by 38% in Q2 2026, selling an estimated $8.6M and leaving 813,589 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

Goldman Sachs first reported a position in NRIX in Q4 2020 and has held it in 23 quarters since. The position peaked at $20.4M in Q4 2025. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Goldman Sachs held 813,589 shares of Nurix Therapeutics worth $19.7M as of Q2 2026.
  • Goldman Sachs sold 505,070 Nurix Therapeutics shares in Q2 2026, an estimated $8.6M.
  • Nurix Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2638 holding.
  • Goldman Sachs first reported a position in Nurix Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Goldman Sachs's Nurix Therapeutics position peaked at $20.4M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.